Your session is about to expire
← Back to Search
Whole Body Vibration for Peripheral Neuropathy
N/A
Waitlist Available
Led By Kerri Winters-Stone, PhD
Research Sponsored by OHSU Knight Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up before and after every whole body vibration session, up to 2 times per day, 7 days per week, for 12 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial studies if whole body vibration can help cancer survivors who have nerve damage from chemotherapy. The treatment involves standing on a vibrating machine to improve movement and reduce pain. The goal is to see if this method is safe and effective for these patients.
Eligible Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Blood Cancers
- Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ before and after every whole body vibration session, up to 2 times per day, 7 days per week, for 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~before and after every whole body vibration session, up to 2 times per day, 7 days per week, for 12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Accrual
Adherence
Adverse events
+1 moreSecondary study objectives
Body mass index
Pain
Exercise readiness
+11 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Whole body vibration (WBV)Experimental Treatment1 Intervention
Participants assigned to the WBV group will participate in twice daily 10-minute WBV training sessions, 7 days a week. Each WBV session will consist of a series of timed stands on the vibration platform (Marodyne LiV). During a timed stand, participants will perform slow controlled weight shifting exercises and gentle squats. The vibration frequency will be set at 30Hz and the amplitude set at 50-200 microns, for a total body acceleration of 0.4g+/-20%.
Group II: Usual Care (UC)Active Control1 Intervention
Participants randomly assigned to the UC group will serve as controls and will be tested at the same time points as the WBV group. The UC group will be asked not to change their physical activity or dietary habits across the intervention period and we will track any changes using a questionnaire.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Whole Body Vibration
2016
Completed Phase 4
~430
Find a Location
Who is running the clinical trial?
OHSU Knight Cancer InstituteLead Sponsor
235 Previous Clinical Trials
2,088,542 Total Patients Enrolled
Oregon Health and Science UniversityOTHER
1,003 Previous Clinical Trials
7,412,352 Total Patients Enrolled
Kerri Winters-Stone, PhDPrincipal InvestigatorOHSU Knight Cancer Institute
3 Previous Clinical Trials
419 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger